Report: IPOs and government support can boost the Australian life sciences industry
Despite a relatively flat December quarter for the PricewaterhouseCoopers Life Sciences Index, it was the end of a very successful calendar year for the Life Sciences sector, according to a new PwC report a report on the listed Australian pharmaceutical, biotechnology and medical devices markets and the broader Life Sciences industry.
In Cautious optimism: The Life Sciences boom and lessons from the past, the report states that a resurgent initial public offering (IPO) market and increased media coverage leave the sector primed for a strong 2014. The current success of the Life Sciences sector gives rise to the question; in the 10 years since the last Australian Biotech boom, what has the sector learnt and how can it capture more value to truly capitalize on its success?
A busy quarter for IPO activity
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze